CARMIEL, Israel, Sept. 14 /PRNewswire/ -- Protalix, Ltd., an Israeli biotechnology company, announced today that it completed the sale of a 14% interest in the company for $15 million to a group of investors led by Dr. Phillip Frost and Glenn L. Halpryn. In connection with the sale, Protalix issued to the investors short-term warrants to acquire an additional 5% of Protalix for an aggregate exercise price of approximately $5.3 million.
